PetMed Q1 Loss Narrows to $6.1M, Sales Stabilize Sequentially
PETS sits 21% above its 52-week low of $1.57 on light trading volume (0.3× avg).
Summary
PetMed Express narrowed its Q1 net loss to $6.1 million from $34.2 million a year ago, with revenue down 19.9% to $41.0 million. Cash fell to $13.1 million, highlighting liquidity pressure.
Key Events · Earnings and Guidance · PETS
-
Q1 Net Loss Narrows
Net loss of $6.1 million ($0.28/share) versus $34.2 million ($1.65/share) in the prior-year quarter, driven by absence of goodwill impairment and lower G&A and advertising expenses.
-
Revenue Declines 19.9%
Net sales of $41.0 million compared to $51.2 million a year ago, with management citing sequential stabilization and lower prescription medication sales.
-
Cash Position Deteriorates
Cash and cash equivalents fell to $13.1 million from $21.4 million at March 31, 2026, reflecting continued operating cash burn of $7.7 million in the quarter.
-
Customer Acquisition Efficiency
Acquired 70,000 new customers while reducing cost per acquisition by 15% year-over-year, a key metric in the company's turnaround strategy.
Analysis · PETS · Trade & Services
PetMed Express reported a first-quarter net loss of $6.1 million, a sharp improvement from the $34.2 million loss a year ago when goodwill and trade name impairments hit the books. Revenue fell 19.9% to $41.0 million, but management emphasized sequential stabilization and a 15% reduction in customer acquisition costs. Cash declined to $13.1 million from $21.4 million at fiscal year-end, underscoring the company's tight liquidity position as it pursues a turnaround amid an activist takeover bid.
At the time of this filing, PETS was trading at $1.90 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $43.4M. The 52-week trading range was $1.57 to $4.10. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.